


## PHARMACEUTICAL 2023



## ROCKET PHARMACEUTICALS INC. Rank 94 of 446





## PHARMACEUTICAL 2023



## ROCKET PHARMACEUTICALS INC. Rank 94 of 446



The relative strengths and weaknesses of ROCKET PHARMACEUTICALS INC. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of ROCKET PHARMACEUTICALS INC. compared to the market average is the variable Liabilities, Current, increasing the Economic Capital Ratio by 42% points. The greatest weakness of ROCKET PHARMACEUTICALS INC. is the variable Other Revenues, reducing the Economic Capital Ratio by 16% points.

The company's Economic Capital Ratio, given in the ranking table, is 202%, being 159% points above the market average of 43%.

| Input Variable                              | Value in<br>1000 USD |
|---|----------------------|
| Assets, Current                             | 364,060              |
| Cost of Goods Sold                          | 0                    |
| Intangible Assets                           | 64,878               |
| Liabilities, Current                        | 39,169               |
| Liabilities, Non-Current                    | 3,683                |
| Other Assets                                | 93,860               |
| Other Compr. Net Income                     | -196                 |
| Other Expenses                              | 1,862                |
| Other Liabilities                           | 19,269               |
| Other Net Income                            | 453                  |
| Other Revenues                              | 3,889                |
| Property and Equipment                      | 29,009               |
| Research and Development                    | 165,570              |
| Selling, General and Administrative Expense | 58,773               |

| Output Variable          | Value in<br>1000 USD |
|--------------------------|----------------------|
| Assets                   | 551,807              |
| Liabilities              | 62,121               |
| Expenses                 | 226,205              |
| Revenues                 | 3,889                |
| Stockholders Equity      | 489,686              |
| Net Income               | -221,863             |
| Comprehensive Net Income | -221,961             |
| Economic Capital Ratio   | 202%                 |